Book Review

Book Review Arch Virol (2007) 152: 1045 DOI 10.1007/s00705-007-0968-3 Printed in the Netherlands Koff WC, Kahn P, Gust I: Aids Vaccine Development. Challenges and Opportunities. 151 pp, Caister Academic Press, 2007. ISBN 978 – 1 – 904455-11-0, $99, £49, EUR 89. It has been estimated that 40 million people were living with chapters that discuss the antigenic diversity of the virus, the HIV=AIDS in 2005 and that 25 million have already died choice of vaccine immunogens, the properties of neutralizing since the epidemic began. Every day, there are 14,000 new monoclonal antibodies, and cell-mediated and mucosal im- HIV infections and 8000 deaths due to AIDS. In some Sub- munity. Part 4 contains five chapters that describe the main Saharan African countries, the HIV prevalence rate is greater candidate vaccines that have been tested in clinical trials than 30% and life expectancy has decreased by nearly 50%. since 1987, emphasizing ongoing Phase I and II trials. The There is no doubt that the HIV=AIDS pandemic is one of first two Phase III HIV vaccine efficacy trials completed in the worst public health issues that humanity is facing today. 2003 showed that the two candidate vaccines that were tested Since the discovery of HIV more than 25 years ago, an did not significantly protect against HIV infection and had no enormous amount of research has been devoted to the virus, impact on viral load in subjects who became HIV-infected making it by far the virus we know most about. It is all the post-vaccination. Data from two ongoing efficacy trials will more extraordinary, therefore, that the most successful inter- not be available until 2009 and it is only in the decade 2010– vention which has halted the spread of viral epidemics in the 2020 that it will become clear if any of the current candidate past, namely the development of a vaccine, has completely vaccines will provide a significant public health benefit. failed in the case of HIV. Several chapters discuss the difficulties of conducting effi- This timely book reviews in considerable detail the nu- cacy trials in developing countries and emphasize how essen- merous scientific challenges and problems that have made tial it is to do this type of work in the resource-poor regions the search for an effective AIDS vaccine so far unsuccessful. that are hardest hit by the epidemic. Part 5 devotes four The editors have secured the help of over 40 internationally chapters to important issues that often receive insufficient known experts in AIDS vaccine research and have assembled attention in discussions of vaccine science, namely vaccine a 19-chapter volume that is essential reading for all those in- scale-up and manufacturing, stringent regulatory issues and terested in current attempts at developing an AIDS vaccine. the need to speed up the transfer of new vaccines from de- The book is divided in five parts. The first part consists of veloped to developing nations two chapters that give a global overview of the epidemic and The book contains about 500 scientific references and a summarize the challenges associated with AIDS vaccine wealth of up to date information. It is highly recommended development. The second part consists of three chapters that for everyone interested in what is no doubt one of the most describe the biology of early HIV infection and our current challenging public health issues of the 21st century. understanding of protective immunity to HIV, including what we have learned from animal models. The third part is M. H. V. van Regenmortel devoted to preclinical vaccine development and contains five CNRS, Strasbourg, France Verleger: Springer-Verlag GmbH, Sachsenplatz 4–6, 1201 Wien, Austria – Herausgeber: Dr. M. H. V. Van Regenmortel, Ecole Superieure de Biotechnologie de Strasbourg (ESBS) Parc d’Innovation, Boulevard Se ´bastian Brandt, 67400 Illkirch, France. – Redaktion: Sachsenplatz 4–6, 1201 Wien, Austria – Hersteller: Satz und Umbruch: Thomson Press (India) Ltd., Chennai; Offsetdruck: Krips bv, Kaapweg 6, 7944 HV Meppel, The Netherlands – Verlagsort: Wien – Herstellungsort: Meppel – Printed in The Netherlands. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Virology Springer Journals
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/book-review-u0cSpp07dl
Publisher
Springer Journals
Copyright
Copyright © 2007 by Springer-Verlag
Subject
Biomedicine; Virology; Medical Microbiology; Infectious Diseases
ISSN
0304-8608
eISSN
1432-8798
D.O.I.
10.1007/s00705-007-0968-3
Publisher site
See Article on Publisher Site

Abstract

Arch Virol (2007) 152: 1045 DOI 10.1007/s00705-007-0968-3 Printed in the Netherlands Koff WC, Kahn P, Gust I: Aids Vaccine Development. Challenges and Opportunities. 151 pp, Caister Academic Press, 2007. ISBN 978 – 1 – 904455-11-0, $99, £49, EUR 89. It has been estimated that 40 million people were living with chapters that discuss the antigenic diversity of the virus, the HIV=AIDS in 2005 and that 25 million have already died choice of vaccine immunogens, the properties of neutralizing since the epidemic began. Every day, there are 14,000 new monoclonal antibodies, and cell-mediated and mucosal im- HIV infections and 8000 deaths due to AIDS. In some Sub- munity. Part 4 contains five chapters that describe the main Saharan African countries, the HIV prevalence rate is greater candidate vaccines that have been tested in clinical trials than 30% and life expectancy has decreased by nearly 50%. since 1987, emphasizing ongoing Phase I and II trials. The There is no doubt that the HIV=AIDS pandemic is one of first two Phase III HIV vaccine efficacy trials completed in the worst public health issues that humanity is facing today. 2003 showed that the two candidate vaccines that were tested Since the discovery of HIV more than 25 years ago, an did not significantly protect against HIV infection and had no enormous amount of research has been devoted to the virus, impact on viral load in subjects who became HIV-infected making it by far the virus we know most about. It is all the post-vaccination. Data from two ongoing efficacy trials will more extraordinary, therefore, that the most successful inter- not be available until 2009 and it is only in the decade 2010– vention which has halted the spread of viral epidemics in the 2020 that it will become clear if any of the current candidate past, namely the development of a vaccine, has completely vaccines will provide a significant public health benefit. failed in the case of HIV. Several chapters discuss the difficulties of conducting effi- This timely book reviews in considerable detail the nu- cacy trials in developing countries and emphasize how essen- merous scientific challenges and problems that have made tial it is to do this type of work in the resource-poor regions the search for an effective AIDS vaccine so far unsuccessful. that are hardest hit by the epidemic. Part 5 devotes four The editors have secured the help of over 40 internationally chapters to important issues that often receive insufficient known experts in AIDS vaccine research and have assembled attention in discussions of vaccine science, namely vaccine a 19-chapter volume that is essential reading for all those in- scale-up and manufacturing, stringent regulatory issues and terested in current attempts at developing an AIDS vaccine. the need to speed up the transfer of new vaccines from de- The book is divided in five parts. The first part consists of veloped to developing nations two chapters that give a global overview of the epidemic and The book contains about 500 scientific references and a summarize the challenges associated with AIDS vaccine wealth of up to date information. It is highly recommended development. The second part consists of three chapters that for everyone interested in what is no doubt one of the most describe the biology of early HIV infection and our current challenging public health issues of the 21st century. understanding of protective immunity to HIV, including what we have learned from animal models. The third part is M. H. V. van Regenmortel devoted to preclinical vaccine development and contains five CNRS, Strasbourg, France Verleger: Springer-Verlag GmbH, Sachsenplatz 4–6, 1201 Wien, Austria – Herausgeber: Dr. M. H. V. Van Regenmortel, Ecole Superieure de Biotechnologie de Strasbourg (ESBS) Parc d’Innovation, Boulevard Se ´bastian Brandt, 67400 Illkirch, France. – Redaktion: Sachsenplatz 4–6, 1201 Wien, Austria – Hersteller: Satz und Umbruch: Thomson Press (India) Ltd., Chennai; Offsetdruck: Krips bv, Kaapweg 6, 7944 HV Meppel, The Netherlands – Verlagsort: Wien – Herstellungsort: Meppel – Printed in The Netherlands.

Journal

Archives of VirologySpringer Journals

Published: May 1, 2007

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off